24.09 16:16 | dpa-AFX: Merck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia Virus |
18.09 13:52 | dpa-AFX: Merck: KEYTRUDA Plus Chemotherapy Gets FDA Approval For Malignant Pleural Mesothelioma In Adults |
18.09 13:20 | dpa-AFX: *MERCK: FDA APPROVES KEYTRUDA PLUS PEMETREXED AND PLATINUM CHEMOTHERAPY FOR ADULT PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA |
18.09 11:44 | dpa-AFX: Merck & Co To Present At Bank Of America Global Healthcare Conference; Webcast At 6:40 AM ET |
17.09 18:21 | MÄRKTE USA/Börsen mit leichten Aufschlägen |
17.09 12:45 | dpa-AFX: Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study |
17.09 12:08 | dpa-AFX: *DAIICHI SANKYO AND MERCK: HERTHENA-LUNG02 PHASE 3 TRIAL OF PATRITUMAB MEETS PRIMARY ENDPOINT |
15.09 18:54 | dpa-AFX: Merck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer Trial |
12.09 13:35 | dpa-AFX: Health Canada Approves Merck's Keytruda As A Monotherapy To Treat MSI-H Or DMMR Solid Tumours |
12.09 13:03 | dpa-AFX: *HEALTH CANADA APPROVES KEYTRUDA AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC MSI-H OR DMMR SOLID TUMOURS |
09.09 22:10 | MÄRKTE USA/Rücksetzer folgt teilweise Erholung - Apple-Präsentation bewegt kaum |
09.09 18:18 | MÄRKTE USA/Aktien nach Rücksetzer auf Wiedergutmachungskurs |
09.09 15:54 | MÄRKTE USA/Wall Street mit leichter Erholung |
09.09 15:31 | dpa-AFX: *MERCK & CO -4% - POSITIVE STUDIE ZU POTENZIELLEM KONKURRENZPRODUKT ZU KEYTRUDA |
09.09 14:56 | MÄRKTE USA/Wall Street vor leichter Erholung |
09.09 12:57 | dpa-AFX: *MERCK & CO -4% VORB. - POSITIVE STUDIENDATEN ZU POTENZIELLER KEYTRUDA-KONKURRENZ |
08.09 04:49 | dpa-AFX: Merck & Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promising Results In Phase 2 Lung Cancer Trial |
05.09 13:02 | dpa-AFX: *MERCK CANADA AND THE PAN-CANADIAN PHARMACEUTICAL ALLIANCE COMPLETE NEGOTIATIONS FOR WELIREG |
05.09 02:59 | dpa-AFX: Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada |
04.09 12:50 | dpa-AFX: *MERCK, EYEBIO UNVEIL COMMENCEMENT OF PHASE 2B/3 TRIAL FOR RESTORET FOR TREATMENT OF DIABETIC MACULAR EDEMA |
|